Neogenomics Inc (NASDAQ: NEO). Notable negative changes in fundamentals have recently occurred: significant quarterly sales deceleration occurred, the consensus estimate for December, 2024 decreased significantly, and the consensus estimate for December, 2025 decreased significantly.
Neogenomics Inc (NASDAQ: NEO). Significant negative changes in investment behavior have recently occurred: its longer term price trend turned down.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, NEO is expected to continue to be Value Creation neutral.
Neogenomics has a current Value Trend Rating of F (Lowest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Neogenomics has a poor Power Rating of 30 and a poor Appreciation Score of 28, resulting in the Lowest Value Trend Rating.
Recent Price Action
Neogenomics Inc (NASDAQ: NEO) stock declined slightly by -0.9% on 6/7/24. The stock closed at $13.01. Trading volume in this decline was normal. The stock has been weak relative to the market over the last nine months and has declined -7.1% during the last week.
Be the first to comment